Larimar Therapeutics, Inc.

The company is a clinical-stage biotechnology firm focused on developing novel treatments for patients suffering from complex, rare, and progressive genetic conditions. Its proprietary cell-penetrating peptide platform enables therapeutic molecules to traverse cellular and organellar membranes to deliver essential proteins to intracellular targets. The firm's lead investigational biologic candidate, nomlabofusp, delivers frataxin into mitochondria to address the underlying cellular deficit in individuals diagnosed with Friedreich's ataxia. Beyond its primary program, the organization works to apply its protein replacement platform across other rare orphan diseases caused by intracellular protein deficiencies.

The company engages with regulatory authorities and conducts research activities internationally. Its clinical programs and planned regulatory filings involve clinical trial sites and health agencies across the United States, the European Union, the United Kingdom, Canada, and Australia. The provided text does not disclose the location of the company's corporate headquarters, nor does it state specific physical facility counts or retail footprints.

Summary of the business section of Larimar Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 71 full-time employees in the United States, of which 55 are directly engaged in research and development with the rest providing administrative, business, commercial and operations support.”